High-throughput drug screening (HTS) assays have enabled investigators to sift through an enormous catalog of potential therapeutic compounds in a fraction of the time that it would take using traditional methodologies. Yet, even with these updated screening procedures, candidate compounds for cancer therapeutics have had a low success rate. However, recently, scientists have begun to harness the power of 3D cell cultures into their HTS workflows. The use of these 3D organoids and spheroid cell models more accurately recapitulates environments within the human body—providing greater enhanced data from screened compounds.

In this GENcast, our guest will tell us more about HTS using 3D cell models and why they are so crucial for current drug discovery projects. Moreover, he will provide scientific insight into the 3D cell panel screening service—called OncoSignature™—which uses a library of 200 cell lines grown in 3D spheroids to provide a better understanding of candidate cancer therapeutics. Take a listen!

 

Panelists:

David Sorrell, PhD
Manager,
Cell Panel Screening
Horizon Discovery

Podcast Sponsored By: